Literature DB >> 26953214

Cellular cardiomyoplasty into infracted swine's hearts by retrograde infusion through the venous coronary sinus: An experimental study.

Edvin Prifti1, Gabriella Di Lascio2, Guy Harmelin3, Daniele Bani4, Vittorio Briganti5, Altin Veshti6, Massimo Bonacchi3.   

Abstract

OBJECTIVES: The aim was to create a model of myocardial infarction with a borderline myocardial impairment which would enable evaluation of the retrograde cellular cardiomyoplasty through the venous coronary sinus in a large animal model.
MATERIALS AND METHODS: Fifteen (study group) and 10 juvenile farm pigs (control group) underwent distal left anterior descending artery ligation. One month later the study group animals underwent sternotomy and a murine myoblastic line C2-C12 was injected at a constant pressure of 30mmHg, into the coronary sinus. Thirty days later all animals that survived from both groups underwent transthoracic echocardiography and 99Tc scintigraphy and were later euthanized and specimens were taken for microscopic evaluation.
RESULTS: Cardiac output decreased significantly after ligation (p<0.001) and increased significantly after cardiomyoplasty (p<0.001). In all animals, the surgical induction of myocardial infarction caused a marked decline in the echocardiographic values of cardiac function; however, the cardiac function and dimensions were significantly improved in the study group after cardiomyoplasty versus the control group. All animals undergoing cardiomyoplasty demonstrated a significant reduction of the perfusion deficit in the left anterior descending artery territory, instead such data remained unchanged in the control group. The histological examination demonstrated the engrafted myoblasts could be distinguished from the activated fibroblasts in the scar tissue because they never showed any signs of collagen secretion and fiber buildup.
CONCLUSIONS: In conclusion, the venous retrograde delivery route through the coronary sinus is safe and effective, providing a significant improvement in function and viability.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Celullar cardiomyoplasty; Coronary sinus; Retrograde infusion

Mesh:

Year:  2016        PMID: 26953214     DOI: 10.1016/j.carrev.2016.02.008

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  5 in total

1.  Therapeutic payload delivery to the myocardium: Evolving strategies and obstacles.

Authors:  Tarek Shazly; Arianna Smith; Mark J Uline; Francis G Spinale
Journal:  JTCVS Open       Date:  2022-05-05

Review 2.  Retrograde Coronary Venous Infusion as a Delivery Strategy in Regenerative Cardiac Therapy: an Overview of Preclinical and Clinical Data.

Authors:  Wouter A Gathier; Dirk Jan van Ginkel; Mira van der Naald; Frebus J van Slochteren; Pieter A Doevendans; Steven A J Chamuleau
Journal:  J Cardiovasc Transl Res       Date:  2018-02-01       Impact factor: 4.132

3.  Scar Formation with Decreased Cardiac Function Following Ischemia/Reperfusion Injury in 1 Month Old Swine.

Authors:  Emma J Agnew; Nivedhitha Velayutham; Gabriela Matos Ortiz; Christina M Alfieri; Luis Hortells; Victoria Moore; Kyle W Riggs; R Scott Baker; Aaron M Gibson; Sithara Raju Ponny; Tarek Alsaied; Farhan Zafar; Katherine E Yutzey
Journal:  J Cardiovasc Dev Dis       Date:  2019-12-18

Review 4.  Efficacy of Stem Cell Therapy in Large Animal Models of Ischemic Cardiomyopathies: A Systematic Review and Meta-Analysis.

Authors:  Debora La Mantia; Chiara Bernardini; Augusta Zannoni; Roberta Salaroli; Changzhen Wang; Silvia Bencivenni; Monica Forni
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

5.  Lower retention after retrograde coronary venous infusion compared with intracoronary infusion of mesenchymal stromal cells in the infarcted porcine myocardium.

Authors:  Wouter A Gathier; Mira van der Naald; Bas R van Klarenbosch; Anton E Tuinenburg; John Lm Bemelmans; Klaus Neef; Joost Pg Sluijter; Frebus J van Slochteren; Pieter A Doevendans; Steven Aj Chamuleau
Journal:  BMJ Open Sci       Date:  2019-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.